drugset / Trial / NCT05353530
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in CD70+ adult glioblastoma
Timeline
- Start
- 2023-07-25
- Primary completion
- 2027-12
- Completion
- 2042-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 8R-70CAR T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | 8R-70CAR T cells | Cell therapy | 1e+07 cells/kg | Intravenous |
| Subject | 8R-70CAR T cells | Cell therapy | 1e+08 cells/kg | Intravenous |